View in EDS

Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.

Saved in:
Bibliographic Details
Title: Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
Authors: Dahal LN; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Huang CY; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Stopforth RJ; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Mead A; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Chan K; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Bowater JX; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Taylor MC; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Narang P; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Chan HTC; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Kim JH; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Vaughan AT; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and., Forconi F; Cancer Sciences Unit, Cancer Research UK and National Institute for Health Research Experimental Cancer Medicine Centres, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom., Beers SA; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and sab@soton.ac.uk.
Source: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2018 Aug 15; Vol. 201 (4), pp. 1211-1221. Date of Electronic Publication: 2018 Jul 11.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 2985117R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29997125
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dahal+LN%22">Dahal LN</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Huang+CY%22">Huang CY</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Stopforth+RJ%22">Stopforth RJ</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Mead+A%22">Mead A</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Chan+K%22">Chan K</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Bowater+JX%22">Bowater JX</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Taylor+MC%22">Taylor MC</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Narang+P%22">Narang P</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Chan+HTC%22">Chan HTC</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Kim+JH%22">Kim JH</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Vaughan+AT%22">Vaughan AT</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.<br /><searchLink fieldCode="AU" term="%22Forconi+F%22">Forconi F</searchLink>; Cancer Sciences Unit, Cancer Research UK and National Institute for Health Research Experimental Cancer Medicine Centres, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Beers+SA%22">Beers SA</searchLink>; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and sab@soton.ac.uk.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985117R%22">Journal of immunology (Baltimore, Md. : 1950)</searchLink> [J Immunol] 2018 Aug 15; Vol. 201 (4), pp. 1211-1221. <i>Date of Electronic Publication: </i>2018 Jul 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985117R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1550-6606 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200221767%22">00221767 </searchLink><i>NLM ISO Abbreviation: </i>J Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29997125
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.4049/jimmunol.1701122
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1211
    Titles:
      – TitleFull: Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dahal LN
      – PersonEntity:
          Name:
            NameFull: Huang CY
      – PersonEntity:
          Name:
            NameFull: Stopforth RJ
      – PersonEntity:
          Name:
            NameFull: Mead A
      – PersonEntity:
          Name:
            NameFull: Chan K
      – PersonEntity:
          Name:
            NameFull: Bowater JX
      – PersonEntity:
          Name:
            NameFull: Taylor MC
      – PersonEntity:
          Name:
            NameFull: Narang P
      – PersonEntity:
          Name:
            NameFull: Chan HTC
      – PersonEntity:
          Name:
            NameFull: Kim JH
      – PersonEntity:
          Name:
            NameFull: Vaughan AT
      – PersonEntity:
          Name:
            NameFull: Forconi F
      – PersonEntity:
          Name:
            NameFull: Beers SA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 08
              Text: 2018 Aug 15
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-electronic
              Value: 1550-6606
          Numbering:
            – Type: volume
              Value: 201
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Journal of immunology (Baltimore, Md. : 1950)
              Type: main
ResultId 1